AcelRx Pharma (ACRX) Completes $10M Common, Warrants Private Placement

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012. Gross proceeds from the offering were approximately $10.0 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes, including the development of the ARX-01 Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• Noodles & Company (NDLS) files $100M mixed shelf
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders